EPOR and cancer: In spite of these beneficial effects, rHuEpo was shown to cause detrimental effects on patient well-being, decreased loco-regional control of disease progression and decreased over-all survival.15–18 Mechanisms of the observed adverse clinical effects have remained elusive, but the most frequently considered hypothesis is the binding of cancer cell EpoR with exogenously administered rHuEpo.